Actively Recruiting
Phase 2 Study to Assess Safety and Effectiveness of JADE101 Injection in Adults With IgA Nephropathy Aged 18 to 60
Led by Jade Biosciences, Inc. · Updated on 2026-07-07
30
Participants Needed
9
Research Sites
12 weeks
Total Duration
AI-Summary
What this Trial Is About
This study evaluates JADE101 in adults aged 18 to 60 with Immunoglobulin A Nephropathy IgAN, aiming to understand its safety and effectiveness. It is a Phase 2, open-label trial conducted by Jade Biosciences, focusing on this kidney condition confirmed by biopsy and treated under standard care. The trials purpose is to contribute to the overall clinical knowledge of JADE101 in this patient group. Participants receive JADE101 through subcutaneous injections. The study includes a single group where all participants receive this treatment. The trial monitors participants from the first dose through up to 100 weeks, assessing both safety and effects on kidney-related measurements, including urine protein and creatinine levels. Throughout the study, participants will attend scheduled visits and comply with treatment plans, laboratory tests, and other procedures. Researchers will track any treatment-related adverse events and changes in urine protein creatinine ratio over the 100-week period. Participants must follow contraceptive and lifestyle guidelines and agree to provide informed consent to participate.
CONDITIONS
Brief Title
A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
Research Team
J
JADE101 Study Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
